NCODA posted on LinkedIn:
“John Marshall, MD, Chief Medical Officer at the Lombardi Comprehensive Cancer Center (Georgetown University Medical Center), discusses zolbetuximab-clzb, a novel treatment for advanced gastric and gastroesophageal junction cancers. This therapy targets CLDN18.2, a protein overexpressed in these cancers, offering a new option for patients.”
Video attached to the post.